Why are we vaccinating children against COVID-19?

Area of Science:

• Pediatric Health
• Infectious Disease Epidemiology
• Vaccine Safety Research

Background:

• COVID-19 mortality is significantly higher in the elderly with comorbidities compared to children.
• Existing clinical trials for pediatric COVID-19 inoculations have limitations in duration, sample size, and population representativeness.
• Long-term effects and biomarker changes post-inoculation in children remain understudied.

Purpose of the Study:

• To critically evaluate the risk-benefit profile of COVID-19 inoculations in pediatric populations.
• To assess the potential long-term implications of pediatric COVID-19 inoculations.
• To compare inoculation-attributed risks versus COVID-19-attributed risks in children.

Main Methods:

• Review of existing COVID-19 mortality data stratified by age.
• Analysis of normalized post-inoculation mortality data.
• A best-case scenario cost-benefit analysis comparing inoculation risks to disease risks.

Main Results:

• COVID-19 attributed deaths per capita are negligible in children.
• Normalized post-inoculation deaths in children are small but not negligible.
• Cost-benefit analysis indicates a significantly higher risk of death from inoculation versus COVID-19 in the elderly (5:1 ratio), suggesting a less favorable ratio for children due to lower COVID-19 risk and unknown long-term effects.

Conclusions:

• The current risk-benefit assessment for pediatric COVID-19 inoculations raises significant concerns due to minimal COVID-19 mortality in this age group and the unknown long-term consequences.
• Further research into long-term safety, biomarker changes, and robust clinical trials with larger, representative pediatric samples are warranted.
• The risk-benefit ratio for pediatric COVID-19 inoculations may be unfavorable, particularly when considering potential long-term adverse effects.